Literature DB >> 33750349

Insulin resistance and high molecular weight adiponectin in obese and non-obese patients with Polycystic Ovarian Syndrome (PCOS).

Farnaz Kamali Haghighi Shirazi1, Zohre Khodamoradi1,2, Marjan Jeddi3.   

Abstract

BACKGROUND: Polycystic ovarian syndrome (PCOS) is the most common endocrinopathy among young women. Insulin resistance is a key feature in the pathogenesis of PCOS; also high molecular weight adiponectin is a marker of insulin resistance. The aim of this study was to evaluate the insulin resistance, metabolic and androgenic profiles and high molecular weight adiponectin in obese and non-obese PCOS patients.
METHODS: In this cross-sectional study in outpatient endocrinology clinics of Shiraz University of Medical Sciences, 80 women aged 17-43 years old with PCOS were enrolled. Biochemical and hormonal assay was done on fasting blood sample on the third day of follicular phase.
RESULTS: The individuals had a mean age of 28.39 ± 6.56 years, mean weight of 65.41 ± 12.59 Kg, mean BMI of 25.5 ± 4.9, and mean waist circumference of 88.0 ± 13.1 cm. Of all individuals 20% had frank insulin resistance with HOMA-IR > 3.8. Although the obese PCOS patients had lower levels of high molecular weight adiponectin (P = 0.03) than the normal weight PCOS individuals, the level of insulin and insulin resistance was not different in them (P = 0.13, 0.13). Patients with classic PCOS phenotype significantly had higher levels of insulin resistance and free androgen index (P < 0.001, 0.001). We found a significant correlation between the insulin level and free androgen index (correlation coefficient: 0.266 and P = 0.018) after adjusting for BMI.
CONCLUSION: This cross-sectional study showed a high incidence of insulin resistance in PCOS patients independent of obesity, and determined BMI related lower level of high molecular weight adiponectin in obese PCOS individuals. More detailed studies are warranted for evaluation of insulin resistance and its pathophysiologic role in PCOS.

Entities:  

Keywords:  Adiponectin; Insulin; Obesity; Polycystic ovary

Year:  2021        PMID: 33750349      PMCID: PMC7941970          DOI: 10.1186/s12902-021-00710-z

Source DB:  PubMed          Journal:  BMC Endocr Disord        ISSN: 1472-6823            Impact factor:   2.763


  2 in total

1.  Association of insulin resistance with lipid profile, metabolic syndrome, and hormonal aberrations in overweight or obese women with polycystic ovary syndrome.

Authors:  Mehranghiz Ebrahimi-Mamaghani; Maryam Saghafi-Asl; Saeed Pirouzpanah; Akbar Aliasgharzadeh; Soudabeh Aliashrafi; Niloufar Rezayi; Mahzad Mehrzad-Sadaghiani
Journal:  J Health Popul Nutr       Date:  2015-03       Impact factor: 2.000

2.  Metabolic Syndrome in Patients with Polycystic Ovary Syndrome in Iran.

Authors:  Ziba Zahiri; Seyedeh Hajar Sharami; Forozan Milani; Fereshteh Mohammadi; Ehsan Kazemnejad; Hannan Ebrahimi; Seyedeh Fatemeh Dalil Heirati
Journal:  Int J Fertil Steril       Date:  2015-12-23
  2 in total
  3 in total

1.  Genetic variation in the ADIPOQ gene and serum adiponectin increase the risk of bladder cancer.

Authors:  Lina Elsalem; Mahmoud A Alfaqih; Samir Al Bashir; Omar Halalsheh; Haneen A Basheer; Khawla Mhedat; Yousef Khader; Klaus Pors
Journal:  J Appl Biomed       Date:  2022-08-03       Impact factor: 0.500

2.  Acetate restores hypothalamic-adipose kisspeptin status in a rat model of PCOS by suppression of NLRP3 immunoreactivity.

Authors:  Kehinde S Olaniyi; Stephanie E Areloegbe; Mosunmola B Oyeleke
Journal:  Endocrine       Date:  2022-09-16       Impact factor: 3.925

3.  Serum adiponectin and cortisol levels are not affected by studied ADIPOQ gene variants: Tehran lipid and glucose study.

Authors:  Masoumeh Nezhadali; Seyed Alireza Mesbah-Namin; Mehdi Hedayati; Mahdi Akbarzadeh; Leila Najd Hassan Bonab; Maryam S Daneshpour
Journal:  BMC Endocr Disord       Date:  2022-04-18       Impact factor: 3.263

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.